Dechra Pharmaceuticals PLC

OTCPK:DPHA.Y Stock Report

Market Cap: US$5.6b

Dechra Pharmaceuticals Valuation

Is DPHA.Y undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DPHA.Y when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DPHA.Y ($98) is trading above our estimate of fair value ($85.93)

Significantly Below Fair Value: DPHA.Y is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DPHA.Y?

Key metric: As DPHA.Y is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for DPHA.Y. This is calculated by dividing DPHA.Y's market cap by their current revenue.
What is DPHA.Y's PS Ratio?
PS Ratio5.8x
SalesUK£761.50m
Market CapUK£4.40b

Price to Sales Ratio vs Peers

How does DPHA.Y's PS Ratio compare to its peers?

The above table shows the PS ratio for DPHA.Y vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.2x
CORT Corcept Therapeutics
9.8x22.6%US$6.2b
JAZZ Jazz Pharmaceuticals
1.9x5.5%US$7.5b
PBH Prestige Consumer Healthcare
3.7x2.4%US$4.2b
ELAN Elanco Animal Health
1.5x3.7%US$6.6b
DPHA.Y Dechra Pharmaceuticals
5.8x7.9%US$4.4b

Price-To-Sales vs Peers: DPHA.Y is expensive based on its Price-To-Sales Ratio (5.8x) compared to the peer average (1.7x).

Price to Sales Ratio vs Industry

How does DPHA.Y's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

70 CompaniesPrice / SalesEstimated GrowthMarket Cap
OGN Organon
0.6x-0.06%US$4.16b
PRGO Perrigo
0.9x3.4%US$3.87b
BHC Bausch Health Companies
0.3x1.5%US$2.92b
AMRX Amneal Pharmaceuticals
1x5.6%US$2.60b
DPHA.Y 5.8xIndustry Avg. 2.9xNo. of Companies70PS048121620+
70 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: DPHA.Y is expensive based on its Price-To-Sales Ratio (5.8x) compared to the US Pharmaceuticals industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is DPHA.Y's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DPHA.Y PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate DPHA.Y's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$57.86

7D

3.9%

1Y

15.0%

Teva Pharmaceutical Industries

US$18.9b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.59

7D

-1.3%

1Y

69.3%

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$31.19

7D

4.8%

1Y

22.3%